The cannabinoid signaling system has recently garnered attention as a therapeutic target for numerous indications, and cannabinoids are now being pursued as new treatment options in diverse medical fields such as neurology, gastroenterology, pain management, and oncology. Cannabinoids are extremely hydrophobic and relatively unstable compounds, and as a result, formulation and delivery options are severely limited. Enzymatic glycosylation is a strategy to alter the physicochemical properties of small molecules, often improving their stability and aqueous solubility, as well as enabling site-specific drug targeting strategies. To determine if cannabinoids are a candidate for glycosylation, a library of glucosyltransferase (UGT) enzymes was screened for glycosylation activity towards various cannabinoids. The UGT76G1 enzyme from Stevia rebaudiana has been identified as having glucosyltransferase activity towards a broad range of cannabinoids. Compounds that were successfully glycosylated by UGT76G1 include the phytocannabinoids cannabidiol (CBD), Δ 9 -tetrahydrocannabinol (Δ 9 -THC), cannabidivarin (CBDV), and cannabinol (CBN), and the human endocannabinoids anandamide (AEA), 2-arachidonoyl-glycerol (2AG), 1-arachidonoyl-glycerol (1AG), and synaptamide (DHEA).
As with synthetic chemistry, in vivo detoxification strategies serve as another model for improving the solubility of cannabinoids. Screening of human liver UGTs against cannabinoids found that cannabinol (CBN) is efficiently glucuronidated by human UGT1A10 in vitro , and minor activity was demonstrated towards CBD with UGT1A9 and UGT2B7 (US8, 410, 064) . Screening of plant cell cultures has shown that CBN is glycosylated when incubated with Pinellia ternata cell cultures (Tanaka 1993) . Similarly, CBD was shown to be glycosylated when incubated with tissue cultures from Pinellia ternata and Datura inoxia , yielding CBD-6'-O-β-D-glucopyranoside and CBD-(2',6')-O-β-D-diglucopyranoside (Tanaka 1996) . These cell culture biotransformation studies demonstrated the potential for limited glycosylation of cannabinoids, but previously, no specific enzymes or methods had been identified that could enable the production of high-purity pharmaceutical preparations or a diverse class of cannabinoid-glycosides.
The plant Stevia rebaudiana produces a diverse family of steviol glycosides and possesses an untapped pool of UGT enzymes, making Stevia an ideal candidate for small-molecule glycosylation screening. UGT76G1 is a glucosyltransferase from Stevia capable of transferring a secondary glucose to the C3-hydroxyl of the primary glycosylation on both C13-OH and C19-COOH positions of the steviol glycoside, and thus its substrates include steviolmonoside, stevioside, rubusoside, RebA, RebD, RebG, and RebE (Richman et al. 2005 , Stevia First Corp unpublished data).
To address the issue of poor cannabinoid solubility and identify methods of producing novel cannabinoid pharmaceutical prodrugs, we screened glucosyltransferase enzymes from Stevia and other organisms to identify candidates for the glycosylation of cannabinoids. We also set out to characterize any resulting cannabinoid glycosides for improved physicochemical properties.
Results: UGT76G1 Glycosylation of Cannabidiol
To identify enzymes with glycosylation activity towards cannabinoids, a Stevia rebaudiana UGT enzyme library was reacted with CBD (Supplemental figure 1). Upon incubation of CBD with the Stevia rebaudiana glucosyltransferase UGT76G1, depletion of the input CBD was observed by RP-HPLC (dotted line, CBD retention time 13.6 min, Figure 1A ). CBD was positively identified in the HPLC line trace based on comparison with the retention time of a purchased CBD standard (Cayman Chemical), along with a doublet fingerprint peak at the cannabinoid absorbance maximum of 275 nm. Prolonged incubation of CBD with UGT76G1 yielded 4 distinct glycoside product mobility groups with retention times of 8. 75, 9.0, 10.3, and 10 .7 minutes, respectively, with other minor products present ( Figure 1A ). Glycosylation of CBD caused a slight shifting of the fingerprint doublet absorbance maximum at 275 nm to 270 nm, which is consistent with other aglycone-to-glycoside conversions ( Figure 1B) . CBD glycosylation was found to be UDPG-dependent, and no direct glycosylation of CBD was observed with other tested enzymes.
In the presence of excess UDPG, UGT76G1 depleted >95% of the input CBD and had an equilibrium constant (Keq) of ~24. LC-ESI-MS was performed on the CBD glycoside mixture resulting from the UGT76G1 CBD reaction, and [M + H] m/z peaks were detected for the CBD aglycone along with the CBD monoside, diglycoside, triglycoside and tetraglycoside (m/z = 315, 477, 639, 801, and 982, respectively, Supplemental Figure 2A ). 1 H-NMR of the purified compounds with HPLC retention times of 9.0 and 10.7 minutes confirmed the production of the CBD diglycosides VB104 and VB110. VB104 is a CBD diglycoside where one available hydroxyl acceptor group has been conjugated with two glucose residues, and its production was confirmed by the presence of two distinct peaks in the aromatic region representing protons 3' and 5' from the substituted resorcinol ring of CBD (6.22 and 6.40 ppm, 1H each, Supplemental Figures 2B, 2C) . VB110 production was confirmed by the presence of one doublet peak in the aromatic region (6.68 ppm, 2H) representing protons 3' and 5', indicating that both the 2' and 6' hydroxyl acceptor groups had been conjugated with a glucose residue (Supplemental Figure   2D ). The determined CBD glycoside structures of UGT76G1 are depicted in Figure 1D .
UGT76G1 Glycosylation of Additional Phytocannabinoids
Based on the efficient glycosylation of the hydroxyl groups of CBD by UGT76G1, additional phytocannabinoids were screened as substrates for UGT76G1, including CBDV, CBN, and Δ 9 -THC. CBDV, a cannabinoid differing from CBD by a three-carbon rather than a five-carbon hydrocarbon tail, was selected to be screened next due to its structural similarity to CBD. CBDV was incubated with UGT76G1 and UDPG in a similar manner as CBD. The reaction was monitored by RP-HPLC and CBDV depletion was observed (CDBV retention time 12.7 min), in addition to the appearance of three additional mobility peaks at 8.5, 9.7, and 10.0 minutes ( Figure 3A ). Formation of these products was dependent on addition of both UGT76G1 and UDPG. The three new products formed displayed the same absorbance characteristics as CBDV and were determined to be the primary glycosides CBDV-2'-O-glucopyranoside or CBDV-6'-O-glucopyranoside, the secondary glycosides CBDV-2'-O-(3-1)-diglucopyranoside or CBDV-6'-O-(3-1)-diglucopyranoside, and CBDV-2',6'-O-diglucopyranoside (compounds VB202/VB206, VB204/VB208, and VB210 respectively). With additional reaction time it was determined that minor product peaks containing higher-order glycosides were also formed, analogous to what was seen when CBD was the substrate. The reaction proceeded to >95% substrate conversion with K eq ~24.
Both the 2' and 6' hydroxyl groups of CBD and CBDV were successfully glycosylated and both compounds exhibit free rotation about the C1' bond between the resorcinol ring and the terpene ring. To determine if the cannabinoids were binding in the active site of UGT76G1 in a rigid conformation or if there was rotation along the C1' bond, Δ 9 -tetrahydrocannabinol (Δ 9 -THC) was screened as a potential substrate. Δ 9 -THC was hypothesized to provide insight into active site binding directionality because it has undergone a ring closure between the 6' hydroxyl group and the terpene ring, thus eliminating any rotation about the C1' bond. Additionally, Δ 9 -THC only has the 2' hydroxyl group free for glycosylation (1-OH based on formal dibenzopyran numbering for Δ 9 -THC). Upon incubation of Δ 9 -THC with UGT76G1 and UDPG, RP-HPLC showed depletion of the input Δ 9 -THC (retention time 14.5 min) and the formation of three main product peaks at 10.6, 10.9, and 11.7 minutes (dotted line, Figure 2B ). The three new products formed displayed a similar UV-VIS absorbance spectrum to Δ 9 -THC (data not shown Figure 2D ). Structures for Δ9-THC are as depicted in Figure 3D .
The final phytocannabinoid that was screened as a substrate for UGT76G1 was the Δ 9 -THC natural degradation product, cannabinol (CBN), which resembles Δ 9 -THC but the upper terpene ring has been fully oxidized to its aromatic form. Upon incubation of CBN with UGT76G1 and UDPG, RP-HPLC showed depletion of the input CBN (CBN retention time 14.2 min) and formation of three main product peaks at 10.8, 11.5 and 12.2 minutes ( Figure 3C ). The three new products displayed the same absorbance characteristics as CBN (data not shown).
Secondary Glycosylation With Os03g0702000p
Branched chain glycosides are often glycosylated by specific enzymes in a stepwise manner, and certain UGTs only recognize a glycoside as their substrate. As UGT76G1 was found to establish primary, secondary, and tertiary glycosylations on the hydroxyl groups of CBD, additional UGTs were screened for their ability to recognize cannabinoid glycosides as substrates for further glycosylation. Os03g0702000p (formerly referred to as EUGT11) is a UGT from Oryza sativa that has secondary glycosylation activity towards steviol glycosides (WO 2013022989). It was tested and determined that Os03g0702000p is capable of transferring an additional glucose moiety from UDPG onto the C2-hydroxyl of the primary sugar established by UGT76G1 (β-2→1 connectivity, Figure 2C ), similar to the secondary glycosylation activity that UGT76G1 has towards the C3-hydroxyl of the primary glucose residue glycosylation (β-3→1 connectivity). Upon incubation of a CBD glycoside mixture generated by UGT76G1 with
Os03g0702000p, four additional glycoside products were formed with HPLC retention times of 9.9, 10.2, 10.3, and 10.6 minutes, which retained the cannabinoid absorbance maxima at 270 nm. This glycosylation activity is consistent with the activity of UGT Os03g0702000p towards steviol glycosides in establishing C2-hydroxyl secondary glycosylations (β-2→1 connectivity) on existing primary glucose residues. Similar glycosylation activity was observed when CBDV, Δ 9 -THC, and CBN glycoside mixtures were incubated with Os03g07000p and excess UDPG (data not shown). All glycoside products were identified based on the retained cannabinoid absorbance maxima at 275 nm. No glycosylation activity was seen when Os03g0702000p alone was incubated with cannabinoids.
UGT76G1 Glycosylation of Endocannabinoids
As UGT76G1 has been determined to recognize a broad class of phytocannabinoids, it was hypothesized that the same enzyme active site may also accommodate and glycosylate endocannabinoids, the endogenous human signaling molecules recognized by the cannabinoid receptors CB1 and CB2 in humans. Accordingly, the endocannabinoids AEA, 2AG, 1AG, and DHEA were obtained and screened as possible substrates for glycosylation by UGT76G1. All endocannabinoid compounds showed UDPG-dependent depletion of the substrates and the formation of new product peaks by RP-HPLC ( Figures 4A, 4B , and 4C, respectively). Upon incubation with UGT76G1 and UDPG, AEA (retention time of 13.9 min) yielded one glycoside product peak with a retention time of 12.5 min ( Figure 4A ). Glycosylation of AEA occurred slowly, and reactions did not proceed to product/substrate ratios seen with phytocannabinoids.
2-AG and 1-AG were obtained in a 90:10 2-AG:1-AG ratio and each displayed an absorbance maximum at 233 nm and RP-HPLC retention times of 14.2 (1-AG) and 14.3 (2-AG) minutes.
Upon incubation with UGT76G1 and UDPG, both compounds showed UDPG-dependent depletion by UGT76G1 ( Figure 4B ). Nine new arachidonoylglycerol-glycoside product peaks were observed on the HPLC trace at 11.4, 11.7, 11.8, 11.9, 12.0, 12.5, 12.9, 13.1, and 13.3 minutes, and all retained the signature 233 nm absorbance maxima ( Figure 4B ). Finally, DHEA, which has an RP-HPLC retention time of 13.7 min and an absorbance maximum of 237 nm, was incubated with UGT76G1 and UDPG. Two new glycoside product peaks were observed in the HPLC line trace at 10.1 and 12.4 minutes, and were identified as glycosides of DHEA as both displayed the signature absorbance maximum of 237 nm ( Figure 4C ).
Physicochemical properties of cannabinoid glycosides
Phytocannabinoids are hydrophobic compounds, which limits their formulation and delivery options for pharmaceutical uses. The cannabinoid glycoside products in the present study all displayed advanced elution from the reverse-phase HPLC separation, suggesting that they are less hydrophobic than their precursors. Based on this observation, it was hypothesized that the cannabinoid glycoside products would have improved aqueous solubility. The standard quantification for chemical solubility is partitioning in water and octanol (log(c octanol /c water ), or ClogP), and recently software has been developed to estimate the ClogP values. Select cannabosides were analyzed and ClogP values were calculated (Table 1 ). The addition of glucose residues to the cannabinoid backbone significantly decreased the ClogP relative to the parent compounds. Δ 9 -THC had a ClogP value of 7.2, but the addition of one glucose residue (VB302) decreased the CLogP value to 5.7, and the addition of two glucose residues (VB304) reduced the value even further to 4.7. To explore how the location of the added sugar residues also affects the CLogP value, CLogP values for CBD were calculated. Compared to Δ 9 -THC, which has one hydroxyl acceptor group, CBD has two hydroxyl acceptor groups at C2' and C6'.
The calculated CLogP value for CBD was 6.6, and the addition of one glucose residue reduced this value to 5.1. With addition of a diglycoside to the hydroxyl group C2' (VB104), the CLogP Because the ClogP values and C18 retention times indicated that cannabosides have decreased hydrophobicity, the aqueous solubility was directly tested ( Figure 5B ,C). Solids in vials were imaged after hydration and mixing by pipetting at 1% in water, followed by 1 minute of vortexing (Figures 5B, C, and D, respectively). The vials contained: 1. water (for reference), 2.
CBD (negative solubility control), 3. VB104, 4. VB110, 5. VB304, 6, saponin (positive foaming control), 7. SDS (positive foaming control), and 8. sucrose (positive solubility, negative foaming control). Pure crystalline CBD was insoluble and water failed to solubilize it. Cannaboside VB104 was hydrated by the added water but the solutions remained cloudy and opaque;
additionally, it possessed detersive properties ( Figure 5D vial 3). VB110 was fully solubilized in water and created a translucent dark liquid. VB304 had partial solubility in water and displayed significant detersive properties. Saponins and SDS were both water soluble and detersive at 1% in water. Finally, sucrose was fully water soluble at 1% and did not display any foaming. The significant foaming shown by VB304 persisted for over 8 hours, whereas the SDS foaming subsided after 1 hour (data not shown).
Discussion:
In the present study, UGT76G1 was capable of transferring primary, secondary, and tertiary (β 3-1) glycosylations onto receptor molecules including phyto-and endocannabinoids. It was also found that UGT76G1 is able to specifically glycosylate both the C2' and C6' hydroxyl groups on CBD and CBDV, in addition to the C1 hydroxyl group of Δ 9 -THC and CBN. Os03g0702000p
from Oryza sativa was capable of transferring secondary (β 2-1) glycosylations onto primary glucose residues established by UGT76G1. The cannabinoid-glycosides produced by these reactions display greatly improved solubility relative to the aglycone precursors and represent a new class of water-soluble cannabinoids termed cannabosides.
The reactions for production of cannabosides are dependent on UDPG, and the products maintain a cannabinoid absorbance spectrum. Multiple CBD-glycoside product peaks are seen on HPLC, and stepwise glycosylation and structural characterization have shown that the products consist of CBD mono, di-, tri-, and tetra-glycosides. All of the CBD glycosides show advanced elution from the C18 column relative to the CBD substrate, indicating a decrease in hydrophobicity. Calculation of the ClogP values for the predominant CBD-glycosides show greatly decreased hydrophobicity compared to the CBD aglycone.
The number of CBD-glycoside product mobility groups indicates multiple glycosylations that occur on both hydroxyl groups. To determine how cannabinoids are coordinated in the active site of UGT76G1, CBD was superpositioned over the bi-functional substrate for UGT76G1, rebaudioside E (RebE) (Supplemental Figure 3 ). The mechanism for dual hydroxyl glycosylation is likely one of two possibilities: either CBD is docking in the UGT76G1 active site both forwards and backwards, creating a cis-like sugar conformation for the glycosylations relative to the cannabinoid backbone (mechanism depicted in Supplemental Figure 4 ), or alternatively, the rotational freedom about the bond at C1' may allow the resorcinol-hydroxyl-glycoside group to rotate 180 degrees after glycosylation, placing the second free hydroxyl group in the active site for glycosylation that occurs in a trans-like conformation relative to the first glycosylation (C6 carbon as described by Mazur 2009 , mechanism depicted in Supplemental Figure 5 ). The difference between these two mechanisms is slight, but they produce structurally distinct glycoside products that may have significantly different properties.
The majority of reactions with UGT76G1 and CBD yielded only diglycosides and higher. Tanaka observed CBD-glycosides after incubating CBD in root cell cultures of Pinellia ternata for periods up to 30 days and did not perform any short-term assays (Tanaka 1996) . As such, Tanaka et al. described difficulty in identifying monoglycosylations of cannabidiol in their biotransformation reactions. Similarly, in this work, UGT76G1 did not produce single glycosylations of CBD in prolonged in vitro enzymatic reactions. This is likely due to the high affinity of CBD-monoglycosides towards the active site of UGT76G1. Short-term kinetic assays with UGT76G1 did produce CBD-monoglycosylations (VB102, VB103) when reactions were stopped using 80% acetonitrile (data not shown). CBD may require two glycosylations to achieve adequate aqueous solubility for escaping the active site of UGT76G1.
Performing enzyme kinetics with UGT76G1 and CBD was complicated by the unique biochemistry of UGT76G1. First, the cannabinoid glycoside products are also substrates for further glycosylation by UGT76G1; therefore, the reactions produce multiple competitive inhibitors very early during the reaction. It was also observed that excess CBD acted to substantially inhibit UGT76G1 reactions; therefore, the substrate concentration needed to be limited to prevent kinetic inhibition of the enzyme (data not shown). Based on this observation, a fed-batch conversion reaction in which CBD was dosed in small amounts on an hourly basis was performed to determine whether maintaining a low concentration of CBD was beneficial to the conversion reaction. Interestingly, this fed-batch reaction preferentially produced VB104, indicating that CBD is the preferred substrate for UGT76G1 when competing with VB104. It was also observed that pre-incubation of UGT76G1 with UDPG resulted in a burst phase of glycoside production that quickly leveled off and appeared to reach a linear, steady-state rate of production of VB104. This initial burst phase likely exhausted the pre-bound UDPG, after which the dissociation of UDP from the active site and concurrent binding of UDPG came to equilibrium.
UGT76G1 exhibited glycosylation activity towards THC that was similar to its activity towards CBD. The multiple THC-glycoside products showed advanced elution from the C18 column and maintained the cannabinoid absorbance spectrum. Similar to CBD, the primary products of UGT76G1 glycosylation were mostly THC-diglycosides and higher. Because LC-ESI-MS clearly revealed a THC-triglycoside, UGT76G1 is capable of transferring up to tertiary glycosides to the same recipient substrate. The fourth product peak was determined to be a glycoside, but the precise structure was not elucidated at the time this manuscript was prepared. It is unlikely to be a THC-tetraglycoside, as the LC-ESI-MS did not indicate a tetraglycoside molecular weight;
rather, it may be a secondary glycosylation other than (β 3-1) attachment, or a degradation product such as CBN-glycoside. Given that the rigid structure of Δ 9 -THC does not have the same rotational freedom as CBD around the C1' resorcinol ring attachment, the cannabinoid backbone is recognized in the active site of UGT76G1 with the Δ 9 -THC C1 hydroxyl group situated towards the UDPG sugar donor (pyran numbering, Figure 1B ).
As originally hypothesized, cannabosides have greatly improved solubility in aqueous solutions.
The solubility is dependent on the number of sugars attached, as well as the position and attachment site of the individual sugars. The highest solubility was observed for VB119 and VB110, CBD-glycosides with glucose molecules on opposing C2' and C6' hydroxyl groups. For VB110, it was found that solutions in excess of 50% w/v (0.78 M) were possible using only water as the solvent (data not shown). Factoring in the molecular mass addition resulting from the two attached sugars, the CBD content is 24.6% by mass, or 0.39 M. This empirically determined aqueous solubility is reinforced by ClogP values calculated in silico using ChemDraw Ultra for phytocannabinoids conjugated with a maximum of two glucose residues.
The ClogP values also show that the number and position of the glycosylations impact the predicted solubility, and validate the aqueous solubility differences seen between the two CBD-diglycosides VB110 (ClogP = 3.4) and VB104 (ClogP = 4.3). Whereas VB110 has glycosylations on opposite sides of the molecule, VB104 is more amphipathic with a hydrophilic glycosylation opposed by the free hydroxyl group. This is more analogous to the THC-glycosides that have lost the free hydroxyl group to ring closure and exhibit a more severely amphipathic structure. During the preparation of aqueous solutions, it was observed that specific cannabosides displayed detersive properties as indicated by foaming while mixing.
This detersive foaming is reminiscent of saponins, which are naturally occurring amphipathic plant glycosides known for their detersive properties, as well as foaming displayed by steviol glycosides (unpublished data). The THC-glycoside VB304 was the most significant detersive molecule, showing greatly increased foaming over saponins and SDS at the same concentration ( Figure 5D ). Interestingly, this foaming was more stable than that of other cannabosides, saponin, and SDS, and persisted for more than 8 hours.
Phytocannabinoids are known to act as agonists, antagonists, and inverse agonists of the human cannabinoid receptors, disrupting the endogenous cannabinoid signaling. This competition at the same active site indicates a functional and structural similarity between phytocannabinoids and endocannabinoids. Based on these similarities, the most well-characterized endocannabinoids were tested, and UGT76G1 was shown to glycosylate all endocannabinoids evaluated. A clear preference was observed for 2-AG and 1-AG compared with the ethanolamides AEA and DHEA. The weak glycosylation activity of UGT76G1 towards anandamide may also be due to non-optimal reaction conditions such as pH, temperature, or specific buffer chemistry, or the ester group of the arachidonoylglycerols may be preferred over the amide group adjacent to the acceptor hydroxyl group of the ethanolamides. Further experimentation with additional endocannabinoids may shed light on the molecular components that contribute to binding within the UGT76G1 active site.
CBD has been published to degrade to THC, CBN, and quinone derivatives by light, heat, and acidic or basic conditions (for review Mechoulam and Hanus, 2002) . Further studies have
shown that orally administered CBD may degrade into the psychoactive THC in simulated gastric fluids containing 1% SDS (Watanabe 2007 , Merrick 2016 . More recently, these in vitro results have been called into question as there is no in vivo evidence to support these claims (Russo 2017, Vitality Bio unpublished results) . In the event that CBD is hydrolyzed to the psychoactive THC by gastric fluids, conjugating sugars to the free hydroxyl groups may protect cannabinoids from conditions that might otherwise produce unwanted cannabinoid byproducts within the stomach.
A growing body of evidence shows that glycosides are capable of acting as prodrugs and have direct therapeutic effects. One example of a class of glycoside pharmaceutical prodrugs is senna glycosides (Senokot, Ex-Lax), which are administered orally, followed by decoupling of the sugars in the large intestine by β-glucosidases secreted from intestinal microbiota (Hardcastle 1970) . Site-specific delivery of steroid glycosides to the colon has also been demonstrated (Friend 1985 , Friend 1984 . Glycosylation of steroids enabled survival of stable bioactive molecules in the acidic stomach environment and delivery into the large intestine,
where the aglycones were decoupled by glycosidases and absorbed into the systemic circulation. Colon-specific delivery of cannabosides and decoupling by local β-glucosidases may enable treatment of colon-specific disorders such as inflammatory bowel disease (IBD),
including Crohn's disease and ulcerative colitis (Kunos 2004) . In addition to facile delivery to the colon, β-glycosidases are also present universally in different tissues; therefore, delivery of cannabosides by methods that bypass the digestive tract and colon, such as intravenous or intranasal delivery, may enable delivery of cannabinoid aglycones to cells and tissues with adequate expression of glucosidases (Conchie 1959) . Additionally, increasing the diversity and complexity of sugar attachments of cannabosides may provide altered distribution and pharmacokinetics in vivo , such as for extended-or delayed-release applications depending on the kinetics of glycoside decoupling. Glycoside prodrugs may thus enable site-specific and tissue-specific drug delivery, which would release simple glucose sugars upon prodrug decoupling. Cannabosides used as prodrugs could ultimately enable novel methods of delivering cannabinoids within the body, including the potential to limit the entry of psychoactive compounds into the bloodstream or brain through well-tolerated oral drug formulation and targeted delivery.
In the course of the present work, it was discovered that UGT76G1 from Stevia rebaudiana is capable of glycosylating a diverse range of substrates beyond steviol glycosides, including both aglycones and glycosides of multiple cannabinoid species. This promiscuous activity is in agreement with data published during the preparation of this manuscript showing that UGT76G1 may be active towards a wide range of substrates ranging from small aglycones to larger glycosides (Dewitte 2016) .
In summary, this collection of novel cannabosides represents a greatly expanded class of cannabinoids with improved physicochemical properties and a wide variety of potential therapeutic applications. Further studies are currently underway to determine the safety and efficacy of these compounds for use as cannabinoid prodrugs.
Materials and Methods:
General water. Solvent A was started at 10% for 4', then ramped to 99% over 10', held at 99% for 4', ramped down to 10% over 2', and held at 10% for 5'. Detection at 202 nm provided the best information for all cannabinoids and cannabinoid glycosides. Cannabinoids and cannabinoid glycosides were identified using reference standards and the observation of a doublet peak at the cannabinoid absorbance maximum of 275 nm. 1 H-NMR spectroscopy was performed on a Bruker Avance II 400 MHz instrument (Emery Pharma) with CD 3 OD as the solvent, using
TopSpin acquisition and processing software. Liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) analysis was conducted on a Shimadzu LCMS 2010EV instrument (Emery Pharma). LC separation was performed using a Silia Chrom XDB C18 5um, 150A, 4.6X50 mm. The method was 12 minutes with a 5 to 95 water:acetonitrile gradient elution. Low-resolution MS was performed in both positive and negative modes. Acetic acid and formic acid were used as sample additives during analysis, and the injection volumes ranged from 5 to 20 µl.
Cloning, Expression, Purification, and Characterization of UGT76G1 and Os03g0702000p.
A Stevia rebaudiana transcriptome library was created. mRNA was extracted from mature stevia leaves using a Spectrum Plant Total RNA extraction kit (Sigma Aldrich). Library preparation and next-gen sequencing were performed on an Illumina HiSeq2000 (Genewiz). Sequence reads were assembled using CLC Genomics Workbench 5.5.1 (Genewiz). The resulting transcriptome was queried with known Stevia UGT proteins via TblastN searches on a local BLAST server.
The cDNA of UGT76G1 was amplified from mRNA via PCR utilizing the Bio-Rad i Script cDNA Synthesis Kit. Os03g0702000p was synthesized (IDT DNA) and PCR to amplify the genes of UGT76G1 and Os03g0702000p was performed utilizing primers listed in Supplementary S1.
The primers were designed to add a 3' HQ tag to UGT76G1 and a 5' HQ tag to Glycosylation reactions for the phytocannabinoids CBD and THC were scaled up proportionally to 100 ml to obtain an adequate amount of glycosylated products for characterization by LC-MS and 1 H NMR. UGT76G1 was deactivated and precipitated from the glycosylation reaction mixture by treatment at 95 °C for 10 minutes. Clarified reaction mixture was obtained by centrifugation. Purification and separation of the glycosylated products is described below.
Glycosylation of Phytocannabinoids and Endocannabinoids with Os03g0702000p.
Glycosylation of selected phytocannabinoids and endocannabinoids by Os03g0702000p was Purification of CBD and THC Glycosides. CBD and THC glycosides were purified by C18 solid phase extraction. Hypersep C18 columns (Thermo) were prepared by hydration in methanol (MeOH), followed by 50% MeOH, then rinsed with di-H2O. UGT76G1 was deactivated and precipitated from the glycosylation reaction mixture by treatment at 95 °C for 10 minutes;
then, the clarified reaction mixture was passed through the column. The column was washed successively with 10 bed volumes of di-H2O,10% MeOH, and 30% MeOH. CBD Glycoside products were eluted with 60% MeOH by volume, whereas THC glycosides were eluted with 80% MeOH by volume. The purity of the glycoside mixtures was analyzed by RP-HPLC as described above. cLogP Calculations. cLogP (logarithm of the partition coefficient between n-octanol and water) calculations were performed using ChemDraw Ultra (CambridgeSoft Corp., Cambridge, MA).
Spectroscopic Analysis of

Empirical Determination of Solubility and Detersiveness. 5 milligrams of cannabosides and
control chemicals were weighed out and added to 2.0ml glass HPLC vials. 500 microliters of sterile distilled water was added and the resulting solution was mixed by pipetting and gentle swirling. Solutions were then vortexed using a laboratory vortexer for 1 minute (VWR Vortex Genie, setting 10). Images were taken at the indicated steps and cropped using GNU Image Manipulation Program, and assembled using Inkscape. Depletion of THC (14.52') was observed upon addition of UDPG, and major product peaks were present at 10.64 ', 10.93', 11.68', and 12.48' (dotted linetrace 
Figure Captions:
Figure 4: UGT76G1 glycosylates endocannabinoids
Anandamide (AEA) was reacted with UGT76G1 in vitro and the reaction was observed by HPLC (A). The control reaction contained all reagents but lacked only the sugar donor UDPG (solid linetrace). Depletion of AEA (13.85') was observed upon addition of UDPG, and the major product peak was present at 12.47' (dotted linetrace). A 9:1 mixture of 2-arachidonoyl-glycerol (2AG) and 1-arachidonoyl-glycerol (1AG) was reacted with UGT76G1 in vitro and the reaction was observed by HPLC (B) . The control reaction contained all reagents but lacked only the sugar donor UDPG (solid linetrace). Depletion of 2AG (14.31') and 1AG (14.18') was observed upon addition of UDPG and major product peaks were present at 11.39 ', 11.70', 11.77', 11.89', 11.97', 12.51', 12.92', 13.07', and 13.32' (dotted linetrace) . Synaptamide (DHEA) was reacted with UGT76G1 in vitro and the reaction was observed by HPLC (C). The control reaction contained all reagents but lacked only the sugar donor UDPG (solid linetrace). Depletion of DHEA (13.75') was observed upon addition of UDPG, and the major product peak was present at 12.42' with minor peaks at 10.09', and 10.21' (dotted linetrace). (D). Endocannabinoid substrates of UGT76G1. The RP-HPLC retention times were determined empirically, and the ClogP values were calculated in silico for a subset of cannabosides, cannabinoids, and cannabinoid-metabolites.
Figure 5: Physicochemical properties of cannabosides
ClogP values for select cannabosides, cannabinoids, and cannabinoid-metabolites from Table 1 were plotted against RP-HPLC retention times to assess linearity (A Linear regression was performed on all data points (R2 = 0.9455) and plotted as the line in (A).
Aqueous solubility and detersive properties are displayed (B, C, and D). Solids in vials (B), hydrated and mixed by pipetting at 1% in water (C), and following 1 minute of vortexing (D).
Vials are as follows: 1. Water, 2. CBD, 3. VB104, 4. VB110, 5. VB304, 6, Saponin, 7. SDS, and 8. Sucrose. 
Supplemental
Supplemental Figure 4: Direct glycosylation model of CBD by UGT76G1
A direct glycosylation model for the biosynthesis of CBD-glycosides by UGT76G1. CBD retains a rigid conformation and does not rotate around the C1' axis. Glycosylations are established as the overall substrate re-positions the recipient hydroxyls towards the enzyme catalytic site.
Supplemental Figure 5: Rotational glycosylation model of CBD by UGT76G1
A rotational model for the biosynthesis of CBD-glycosides by UGT76G1. After establishing one or two glycosylations on one of the hydroxyl groups of CBD, the rotational freedom along the C1' axis allows the resorcinol ring to rotate and swing the second hydroxyl group towards the catalytic site of UGT76G1.
Supplemental Figure 6: Oligonucleotide sequences
Primers used for the amplification and cloning of UGT76G1 and Os03g0702000. 
